Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ndjeka

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
The European Respiratory Journal|May 31, 2020
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?Norbert Ndjeka, Francesca Conradie, Graeme Meintjes, et al.
Tropical Medicine and Infectious Disease|December 24, 2025
Evaluating the New TB Antigen-Based Skin Test to Diagnose TB Infection in South AfricaFarzana Sathar, Claire du Toit, Violet Chihota, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 10, 2026
Treatment Outcomes and Drug-Related Adverse Events Across Four Short-Course RR-TB Regimens in South Africa: A Retrospective AnalysisNorbert Ndjeka, Rubeshan Perumal, Kamila Romanowski, et al.
BMJ Open|November 17, 2023
Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods studyLindy Dickson, Sacha Roxanne Le Roux, Leila Mitrani, et al.
BMC Infectious Diseases|November 22, 2022
Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysisHelen Pai, Norbert Ndjeka, Lawrence Mbuagbaw, et al.
BMJ Open|December 4, 2021
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesGabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, et al.
The Lancet. Infectious Diseases|May 5, 2022
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort studyNorbert Ndjeka, Jonathon R Campbell, Graeme Meintjes, et al.
The Lancet. Global Health|August 12, 2022
Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort studyMurray Dryden, Caroline Mudara, Caroline Vika, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2026
When are uncontrolled trials in TB scientifically and ethically justified: Borrowing wisdom from early AIDS clinical trialsLindsay McKenna, Mike Frick, Valentina A Alarcón-Guizado, et al.
Plos One|January 5, 2024
Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026Aastha Gupta, Sandeep Juneja, Victor Babawale, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
The European Respiratory Journal|May 31, 2020
Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?Norbert Ndjeka, Francesca Conradie, Graeme Meintjes, et al.
Tropical Medicine and Infectious Disease|December 24, 2025
Evaluating the New TB Antigen-Based Skin Test to Diagnose TB Infection in South AfricaFarzana Sathar, Claire du Toit, Violet Chihota, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 10, 2026
Treatment Outcomes and Drug-Related Adverse Events Across Four Short-Course RR-TB Regimens in South Africa: A Retrospective AnalysisNorbert Ndjeka, Rubeshan Perumal, Kamila Romanowski, et al.
BMJ Open|November 17, 2023
Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods studyLindy Dickson, Sacha Roxanne Le Roux, Leila Mitrani, et al.
BMC Infectious Diseases|November 22, 2022
Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysisHelen Pai, Norbert Ndjeka, Lawrence Mbuagbaw, et al.
BMJ Open|December 4, 2021
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the PhilippinesGabriela Beatriz Gomez, Mariana Siapka, Francesca Conradie, et al.
The Lancet. Infectious Diseases|May 5, 2022
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort studyNorbert Ndjeka, Jonathon R Campbell, Graeme Meintjes, et al.
The Lancet. Global Health|August 12, 2022
Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort studyMurray Dryden, Caroline Mudara, Caroline Vika, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2026
When are uncontrolled trials in TB scientifically and ethically justified: Borrowing wisdom from early AIDS clinical trialsLindsay McKenna, Mike Frick, Valentina A Alarcón-Guizado, et al.
Plos One|January 5, 2024
Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026Aastha Gupta, Sandeep Juneja, Victor Babawale, et al.
Pageof 6